Loading stock data…
$2.91+0.01 (+0.34%)
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Incannex Healthcare Inc. in the Healthcare sector is trading at $2.91 with a market capitalization of $44M. Wall Street consensus targets $18.69 (2 analysts), implying a +542.1% move over the next 12 months. The stock is currently near its 52-week low of $2.49, remaining 39.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | — | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.97M↑ | -$6.51M↓ | -$6.41M | — | -$4.58M |
| Net Income | -$3.88M↑ | -$6.52M↓ | -$6.41M↑ | -$7.48M↓ | -$3.97M |
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose com...